Author: Ravi Shankar

BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has entered into a strategic research collaboration and license agreement with Eli Lilly and Company (“Lilly”) to develop new medicines.

InnoCare will leverage its proprietary drug discovery platform and extensive research experience to discover and advance compounds against up to five targets to address critical unmet medical needs.

“We are excited to leverage our R&D platform to collaborate with a global pharmaceutical leader like Lilly,” said Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare. “We are dedicated to expanding our partnership and innovation footprint.”

Under the terms of the agreement, InnoCare will be eligible to receive up to $100 million in upfront and near-term payments, and up to approximately $3.25 billion in development and commercial milestone payments. In addition, InnoCare will be eligible to receive single-digit tiered royalties based on annual net product sales.

About InnoCare Pharma

InnoCare (HKEX: 09969; SSE: 688428) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing innovative drugs for the treatment of cancers and autoimmune diseases, two therapeutic areas with unmet medical needs worldwide. InnoCare has established comprehensive innovation platforms for drug discovery. To date, the Company has developed a robust product pipeline comprising three approved drugs (orelabrutinib, tafasitamab and zurletrectinib), more than ten innovative drug candidates in clinical development, and multiple programs in preclinical stages. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong SAR, and the United States. For more information about InnoCare, please visit https://www.innocarepharma.com/en and follow us on LinkedIn.

Forward-Looking Statements
This release contains certain forward-looking statements. All statements, other than statements of fact, could be considered forward-looking statements, meaning statements regarding actions, events, or developments that we or our management intend, expect, project, believe, or anticipate will or may occur in the future. These statements are based on assumptions and estimates made by our management in light of their experience and perception of historical trends, current conditions, expected future developments, and other relevant factors. Forward-looking statements are not guarantees of future performance, and actual results, developments, and business decisions may differ materially from those contemplated by these forward-looking statements. Our forward-looking statements are subject to a number of risks and uncertainties that could affect our near- and long-term performance.

Cautionary Statement
The payments in this research collaboration and license agreement are subject to certain conditions. There is still uncertainty regarding the final payment.

Contact
Media	Investors
Chunhua Lu
86-10-66609879 chunhua.lu@innocarepharma.com	86-10-66609999 ir@innocarepharma.com

Press contact:
Fahd Pasha
Tel.: +1 647 860 3777
E-mail: Fahd.Pasha@capgemini.com

Banks risk losing $230 billion in payments revenue as stablecoins and tokenized deposits go mainstream

• Stablecoins, tokenized deposits and central bank digital currencies expected to account for 4% of global payments volume by 2030
• Nearly 60% of corporates open to sourcing stablecoin services from non-bank providers
• Tokenized deposits emerge as banks’ top near-term priority to retain deposits and preserve liquidity
• USD 4 trillion of capital trapped in accounts to fund cross-border payment flows

Paris, September 24, 2026 – The global payments industry is approaching a tipping point. As stablecoins, tokenized depositsⁱ, and central bank digital currencies (CBDCs) move from experimentation to commercialization, banks face mounting pressure on traditional payments revenue pools. According to the Capgemini Research Institute’s World Payments Report 2027, these instruments are projected to account for approximately 4% of the global payments volume by 2030, impacting high-margin revenue streams such as foreign exchange spreads, correspondent banking, float income, and transaction processing fees.

Banks have prioritized payment innovation for corporate clients over the last three years with 60% identifying it as a strategic area of investment. However, only one in three corporate clients are satisfied with their primary banking partner, revealing a widening gap between what banks are delivering and what businesses increasingly expect.

Nearly three-quarters (74%) of corporates describe cross-border payments as slow, costly, and unpredictable. The end-to-the-end journey for corporate payments, from origination and transfer to confirmation and reconciliation, takes roughly 3.5 days. During that process, more than half (57%) report lacking access to live payment status, cash positions, or transparent pricing. Corporates rank predictability of settlement outcomes, real-time visibility into payment execution, and stronger protection against fraud among their most persistent unmet needs. As a result, corporates incur total costs equivalent to 2% of transaction value for a typical cross-border business-to-business (B2B) payment.

Now in its 22^nd edition, the new report surveyed over 1,100 large corporates with revenues greater than USD 1 billion. On average, respondents indicate they operate in 14 markets, maintain 11 banking relationships, and conduct 34% of their B2B payment volume through cross-border transactions. Despite improvements in payment infrastructure, operational fragmentation remains the most defining challenge for corporate clients.

Accelerated intelligent money instruments emerge as a catalyst for transformation
Structural limitations in B2B payment infrastructure, regulatory clarity, and shifting market dynamics are driving the emergence of what the report defines as “accelerated intelligent money” – stablecoins, tokenized deposits, and CBDCs that enable money to do more than simply move between accounts. By supporting 24/7 execution, built-in rules and real-time settlement, these instruments can reduce friction during cross-border payment flows. The report estimates that widespread adoption could unlock as much as USD 4 trillion currently trapped in settlement and liquidity accounts – capital that generates little return and cannot be deployed for lending, investment or other productive uses.

Corporate demand is already building for this new generation of payment instruments and banks remain the preferred provider: 71% of corporates would choose a bank over a fintech for tokenized payments at equivalent cost and quality. However, that preference is not guaranteed. Nearly 60% of corporate clients are willing to source stablecoin services from non-bank providers if their banking partners fail to keep pace. This competitive erosion arrives as corporate clients report 36% of their B2B payment volume already flows through non-banks.

“The payments industry is entering its most significant period of disruption since the emergence of digital banking,” said Jeroen Hölscher, Global Head of Payment Services at Capgemini. “We are moving past the intelligent money hype cycle into a period where the economics and transaction volumes make it impossible for banks to remain on the sidelines. With $230 billion at stake, banks must decide what role they want to play in this emerging ecosystem. A select group of banks have already made their choice and are now shaping the standards and governance that will define the market. Those that act now will build lasting trust, capture new payment flows, and retain the corporate deposits that underpin their wider banking relationships.”

Banks identify tokenized deposits as key priority
As intelligent money moves toward commercialization, banks must define their strategic position in this ecosystem. The report finds that bank executives identify tokenized deposits as the top near-term priority for their ability to remain on balance sheets and fit within existing regulations. However, only 21% of banks – classified as leaders – are actively scaling at least one accelerated intelligent money instrument, while the remaining 79% of banks are still evaluating their position.

These high-achieving banks are focused on specific corporate use cases that address operational friction and monetize their value beyond transaction fees. The payoff is measurable as these leaders are three times more likely than mainstream banks to identify new revenue streams and expect to offset declining transaction revenue within 15 months, versus 25 months for rest of the industry. They are also more decisive: 33% of leaders aim to pursue a transformative market posture by shaping how the ecosystem operates, compared with 40% of mainstream banks that intend to take a reactive approach.

According to the report, since settlement with intelligent money is irrevocable, leaders place a premium on compliance by embedding it directly into execution before money moves. They outpace mainstream banks by 1.5 times on cross-network transaction monitoring and are 1.2 times more likely to both invest in AI-driven surveillance to flag unusual wallet behavior and implement real-time Anti-Money Laundering (AML) and Know Your Customer (KYC) checks into transaction flows.

Yet even among leaders, foundational gaps remain. Just over half (56%) report having the talent and skills to build and maintain digital assets, technical readiness, and capabilities required to support tokenization, smart contracts, and interoperability across financial networks. Closing that gap will determine which banks are best positioned to move from experimentation to scale.

Read the full report: World Payments Report 2027 – Now Money Really Never Sleeps

Methodology

The World Payments Report 2027 draws on two primary research sources. The 2026 Global Corporate Survey, conducted from May to June 2026 in collaboration with INJ Partners, surveyed 1,110 large corporates with revenues greater than USD 1 billion across nine countries. Respondents were equally distributed across insurance, manufacturing and logistics/transportation. The Global Banking Executives Survey, conducted during the same period, surveyed 300 banking executives across nine markets: Australia, France, Germany, Hong Kong, the Netherlands, Singapore, the UAE, the UK and the US. Banks classified as “leaders” are actively scaling at least one accelerated intelligent money instrument, while mainstream banks are still piloting, evaluating or not considering these instruments.

About Capgemini

Capgemini is the business transformation partner for enterprises in the age of AI. We help organizations imagine and build an intelligent, sustainable future, combining AI, technology and human ingenuity to transform how they operate, innovate and grow. With unique end-to-end capabilities spanning strategy, technology, engineering and intelligent operations, we bring together deep industry expertise and market-leading capabilities in AI, cloud and data to turn ambition into measurable business outcomes at scale. Supported by a robust ecosystem of partners and nearly 60 years of expertise, Capgemini is a responsible and diverse global organization of over 410,000 team members in more than 50 countries. The Group reported 2025 revenues of €22.5 billion.

Make it real | www.capgemini.com

About the Capgemini Research Institute
The Capgemini Research Institute is Capgemini’s in-house think-tank on all things digital. The Institute publishes research on the impact of digital technologies on large traditional businesses. The team draws on the worldwide network of Capgemini experts and works closely with academic and technology partners. The Institute has dedicated research centers in India, Singapore, the United Kingdom and the United States. It was ranked #1 in the world for the quality of its research by independent analysts for six consecutive times – an industry first.

Visit us at https://www.capgemini.com/researchinstitute/

---

ⁱ Stablecoins are digital currencies whose value is tied to a traditional currency, while tokenized deposits are traditional bank deposits issued as digital tokens on a blockchain

Attachment

• 09_24_Capgemini Press Release_World Payments Report 2027

• Follows the launch of MoneyHero’s Hong Kong life insurance marketplace, supporting its strategy to grow high-margin verticals and deepen member engagement
• Features 13 plans from five insurers, Blue, Bowtie, FWD, OneDegree and Zurich, with coverage amounts of up to HK$4 million

HONG KONG, Sept. 24, 2026 (GLOBE NEWSWIRE) — MoneyHero Limited (NASDAQ: MNY) (“MoneyHero” or the “Company”), a leading tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia, today announced the launch of critical illness insurance comparison in Hong Kong, further broadening the range of insurance products on its platform.

The launch is the first product delivery on the second-half 2026 product roadmap MoneyHero outlined on its second quarter 2026 earnings call. It will be integrated into and builds upon the life insurance marketplace introduced during the second quarter of 2026, supporting the continued expansion into high-margin verticals.

Critical illness insurance generally provides a lump-sum cash payout upon the diagnosis of a covered condition, such as cancer, heart attack, or stroke, giving policyholders financial flexibility to help cover medical costs, replace lost income, or support their recovery.

The marketplace will offer 13 plans from five insurers (in alphabetical order): Blue, Bowtie, FWD, OneDegree, and Zurich, ranging from entry-level protection to more comprehensive plans covering up to 71 conditions with coverage amounts of up to HK$4 million. Users can filter by age, gender, and smoker status for instant, personalised quotes, compare single-claim and multiple-claim options, and click through directly to their chosen insurer to complete the application.

With this launch, consumers can compare life, travel, and medical insurance products on MoneyHero’s platform, drawing on offerings from a range of established insurers. The addition of critical illness coverage reflects growing consumer demand for a simple, self-guided way to research and apply for protection products online.

“Critical illness insurance is an important addition to our insurance offerings, and one that reflects real demand we’re seeing from Hong Kong consumers,” said Danny Leung, Interim CEO and CFO. “Comparing critical illness insurance can feel overwhelming, with dense policy documents and unfamiliar terms. Our goal is to make the process simple and transparent, enabling customers to compare options from various insurers and choose the coverage that best fits their needs. This launch builds on the momentum of our life insurance marketplace and reinforces our strategy to grow our presence in high-margin verticals. It also lays the groundwork for the further protection and savings products in the coming quarters.”

Hong Kong consumers can start comparing plans today at https://www.moneyhero.com.hk/zh/insurance/critical-illness-insurance

About MoneyHero Group

MoneyHero Limited (NASDAQ: MNY) is a tech- and AI-powered personal finance aggregation and comparison platform that provides consumers with actionable insights to discover, compare, and choose the best financial products with confidence — bringing data intelligence and seamless digital access across insurance and banking solutions. The Company operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The Company also retains an equity stake in Malaysian fintech company, Jirnexu Pte. Ltd., parent company of Jirnexu Sdn.Bhd., the operator of Ringgit Plus, Malaysia’s largest operating B2C platform. MoneyHero had over 280 commercial partner relationships as at June 30, 2026, and had approximately 3.7 million Monthly Unique Users across its platform for the three months ended June 30, 2026. The Company’s backers include Peter Thiel—co-founder of PayPal, Palantir Technologies, and the Founders Fund—and Hong Kong businessman, Richard Li, the founder and chairman of Pacific Century Group. To learn more about MoneyHero and how the innovative fintech company is driving APAC’s digital economy, please visit www.MoneyHeroGroup.com.

Forward Looking Statements

This document includes “forward-looking statements” within the meaning of the United States federal securities laws and also contains certain financial forecasts and projections. All statements other than statements of historical fact contained in this communication, including, but not limited to, statements as to the Company’s growth strategies, future results of operations and financial position, market size, industry trends and growth opportunities, are forward-looking statements. Undue reliance should not be placed upon the forward-looking statements.

For MoneyHero inquiries, please contact:

Investor Relations:
IR@MoneyHeroGroup.com

Media Relations:
Press@MoneyHeroGroup.com

• Follows the launch of MoneyHero’s Hong Kong life insurance marketplace, supporting its strategy to grow high-margin verticals and deepen member engagement
• Features 13 plans from five insurers, Blue, Bowtie, FWD, OneDegree and Zurich, with coverage amounts of up to HK$4 million

HONG KONG, Sept. 24, 2026 (GLOBE NEWSWIRE) — MoneyHero Limited (NASDAQ: MNY) (“MoneyHero” or the “Company”), a leading tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia, today announced the launch of critical illness insurance comparison in Hong Kong, further broadening the range of insurance products on its platform.

The launch is the first product delivery on the second-half 2026 product roadmap MoneyHero outlined on its second quarter 2026 earnings call. It will be integrated into and builds upon the life insurance marketplace introduced during the second quarter of 2026, supporting the continued expansion into high-margin verticals.

Critical illness insurance generally provides a lump-sum cash payout upon the diagnosis of a covered condition, such as cancer, heart attack, or stroke, giving policyholders financial flexibility to help cover medical costs, replace lost income, or support their recovery.

The marketplace will offer 13 plans from five insurers (in alphabetical order): Blue, Bowtie, FWD, OneDegree, and Zurich, ranging from entry-level protection to more comprehensive plans covering up to 71 conditions with coverage amounts of up to HK$4 million. Users can filter by age, gender, and smoker status for instant, personalised quotes, compare single-claim and multiple-claim options, and click through directly to their chosen insurer to complete the application.

With this launch, consumers can compare life, travel, and medical insurance products on MoneyHero’s platform, drawing on offerings from a range of established insurers. The addition of critical illness coverage reflects growing consumer demand for a simple, self-guided way to research and apply for protection products online.

“Critical illness insurance is an important addition to our insurance offerings, and one that reflects real demand we’re seeing from Hong Kong consumers,” said Danny Leung, Interim CEO and CFO. “Comparing critical illness insurance can feel overwhelming, with dense policy documents and unfamiliar terms. Our goal is to make the process simple and transparent, enabling customers to compare options from various insurers and choose the coverage that best fits their needs. This launch builds on the momentum of our life insurance marketplace and reinforces our strategy to grow our presence in high-margin verticals. It also lays the groundwork for the further protection and savings products in the coming quarters.”

Hong Kong consumers can start comparing plans today at https://www.moneyhero.com.hk/zh/insurance/critical-illness-insurance

About MoneyHero Group

MoneyHero Limited (NASDAQ: MNY) is a tech- and AI-powered personal finance aggregation and comparison platform that provides consumers with actionable insights to discover, compare, and choose the best financial products with confidence — bringing data intelligence and seamless digital access across insurance and banking solutions. The Company operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The Company also retains an equity stake in Malaysian fintech company, Jirnexu Pte. Ltd., parent company of Jirnexu Sdn.Bhd., the operator of Ringgit Plus, Malaysia’s largest operating B2C platform. MoneyHero had over 280 commercial partner relationships as at June 30, 2026, and had approximately 3.7 million Monthly Unique Users across its platform for the three months ended June 30, 2026. The Company’s backers include Peter Thiel—co-founder of PayPal, Palantir Technologies, and the Founders Fund—and Hong Kong businessman, Richard Li, the founder and chairman of Pacific Century Group. To learn more about MoneyHero and how the innovative fintech company is driving APAC’s digital economy, please visit www.MoneyHeroGroup.com.

Forward Looking Statements

This document includes “forward-looking statements” within the meaning of the United States federal securities laws and also contains certain financial forecasts and projections. All statements other than statements of historical fact contained in this communication, including, but not limited to, statements as to the Company’s growth strategies, future results of operations and financial position, market size, industry trends and growth opportunities, are forward-looking statements. Undue reliance should not be placed upon the forward-looking statements.

For MoneyHero inquiries, please contact:

Investor Relations:
IR@MoneyHeroGroup.com

Media Relations:
Press@MoneyHeroGroup.com

• Follows the launch of MoneyHero’s Hong Kong life insurance marketplace, supporting its strategy to grow high-margin verticals and deepen member engagement
• Features 13 plans from five insurers, Blue, Bowtie, FWD, OneDegree and Zurich, with coverage amounts of up to HK$4 million

HONG KONG, Sept. 24, 2026 (GLOBE NEWSWIRE) — MoneyHero Limited (NASDAQ: MNY) (“MoneyHero” or the “Company”), a leading tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia, today announced the launch of critical illness insurance comparison in Hong Kong, further broadening the range of insurance products on its platform.

The launch is the first product delivery on the second-half 2026 product roadmap MoneyHero outlined on its second quarter 2026 earnings call. It will be integrated into and builds upon the life insurance marketplace introduced during the second quarter of 2026, supporting the continued expansion into high-margin verticals.

Critical illness insurance generally provides a lump-sum cash payout upon the diagnosis of a covered condition, such as cancer, heart attack, or stroke, giving policyholders financial flexibility to help cover medical costs, replace lost income, or support their recovery.

The marketplace will offer 13 plans from five insurers (in alphabetical order): Blue, Bowtie, FWD, OneDegree, and Zurich, ranging from entry-level protection to more comprehensive plans covering up to 71 conditions with coverage amounts of up to HK$4 million. Users can filter by age, gender, and smoker status for instant, personalised quotes, compare single-claim and multiple-claim options, and click through directly to their chosen insurer to complete the application.

With this launch, consumers can compare life, travel, and medical insurance products on MoneyHero’s platform, drawing on offerings from a range of established insurers. The addition of critical illness coverage reflects growing consumer demand for a simple, self-guided way to research and apply for protection products online.

“Critical illness insurance is an important addition to our insurance offerings, and one that reflects real demand we’re seeing from Hong Kong consumers,” said Danny Leung, Interim CEO and CFO. “Comparing critical illness insurance can feel overwhelming, with dense policy documents and unfamiliar terms. Our goal is to make the process simple and transparent, enabling customers to compare options from various insurers and choose the coverage that best fits their needs. This launch builds on the momentum of our life insurance marketplace and reinforces our strategy to grow our presence in high-margin verticals. It also lays the groundwork for the further protection and savings products in the coming quarters.”

Hong Kong consumers can start comparing plans today at https://www.moneyhero.com.hk/zh/insurance/critical-illness-insurance

About MoneyHero Group

MoneyHero Limited (NASDAQ: MNY) is a tech- and AI-powered personal finance aggregation and comparison platform that provides consumers with actionable insights to discover, compare, and choose the best financial products with confidence — bringing data intelligence and seamless digital access across insurance and banking solutions. The Company operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The Company also retains an equity stake in Malaysian fintech company, Jirnexu Pte. Ltd., parent company of Jirnexu Sdn.Bhd., the operator of Ringgit Plus, Malaysia’s largest operating B2C platform. MoneyHero had over 280 commercial partner relationships as at June 30, 2026, and had approximately 3.7 million Monthly Unique Users across its platform for the three months ended June 30, 2026. The Company’s backers include Peter Thiel—co-founder of PayPal, Palantir Technologies, and the Founders Fund—and Hong Kong businessman, Richard Li, the founder and chairman of Pacific Century Group. To learn more about MoneyHero and how the innovative fintech company is driving APAC’s digital economy, please visit www.MoneyHeroGroup.com.

Forward Looking Statements

This document includes “forward-looking statements” within the meaning of the United States federal securities laws and also contains certain financial forecasts and projections. All statements other than statements of historical fact contained in this communication, including, but not limited to, statements as to the Company’s growth strategies, future results of operations and financial position, market size, industry trends and growth opportunities, are forward-looking statements. Undue reliance should not be placed upon the forward-looking statements.

For MoneyHero inquiries, please contact:

Investor Relations:
IR@MoneyHeroGroup.com

Media Relations:
Press@MoneyHeroGroup.com

Bogota, Colombia, Sept. 23, 2026 (GLOBE NEWSWIRE) — GeoPark Limited (NYSE: GPRK) (the “Company”) today announced that it has received the requisite consents in connection with its previously announced solicitation of consents (the “Consent Solicitation”) from holders of its 8.750% Senior Notes due 2030 (the “Notes”). The Consent Solicitation was made pursuant to a Consent Solicitation Statement, dated September 15, 2026 (as amended, supplemented or otherwise modified, the “Consent Solicitation Statement”). The proposed amendment (the “Proposed Amendment”) to the indenture (the “Indenture”) governing the Notes is to amend the definition of “Permitted Holders” in the Indenture to include Jaime Gilinski Bacal and his Immediate Family Members (as defined in the Indenture) or the former spouses (including widows and widowers), heirs or lineal descendants of any of the foregoing and any Affiliate of any of the foregoing. Jaime Gilinski Bacal is affiliated with Grupo Gilinski, which through affiliated entities has through a number of transactions recently purchased approximately 28% of the Company’s issued and outstanding common shares. GeoPark’s recently announced proposed major strategic entry into Venezuela through the Bare field, a large-scale producing heavy oil asset located in the Orinoco Heavy Oil Belt, was led by Grupo Gilinski. GeoPark is acquiring Grupo Gilinski’s 95% interest in the holding company through which the Bare opportunity is held in exchange for newly issued common shares. The proposed transaction has not yet closed and remains subject to certain conditions. Upon completion of the share issuance, Grupo Gilinski is expected to hold approximately 56.3% of GeoPark’s issued and outstanding common shares. Pursuant to the Indenture, a “Change of Control” will generally not be triggered by the consummation of a transaction the result of which is that a Permitted Holder becomes the beneficial owner of more than 50% of the outstanding shares. Pursuant to the Indenture, if a Change of Control occurs, the Company is required to make an Offer to Purchase (as defined in the Indenture) for all of the outstanding Notes.

The Company has been advised that it has received consents from holders of a majority of the aggregate principal amount of the Notes (not including Notes held by the Company or any of its affiliates) (the “Requisite Consents”). In connection with the receipt of the Requisite Consents, the Company expects to execute a supplemental indenture to the Indenture to effect the Proposed Amendment with respect to the Notes on September 29, 2026. The Company will make a cash payment equal to $2.50 per $1,000 principal amount of Notes (the “Consent Fee”) to holders of the Notes on the applicable record date that delivered their consents prior to September 23, 2026 at 5:00 p.m., New York City time (the “Expiration Time”) and did not revoke such consents. The Company expects to pay the Consent Fee on September 29, 2026. No Consent Fee will be paid to any holder of the Notes unless such holder delivered (and did not revoke) a consent in accordance with the terms of the Consent Solicitation Statement prior to the Expiration Time. The supplemental indenture will become effective upon its execution and delivery by the Company and the trustee but will provide that the Proposed Amendment will not become operative until the Company has paid the Consent Fee in full.

Banco BTG Pactual S.A. – Cayman Branch acted as solicitation agent for the Consent Solicitation and D.F. King & Co., Inc. acted as the information agent, tabulation agent and paying agent for the Consent Solicitation.

Neither the Consent Solicitation nor any related documents have been filed with the U.S. Securities and Exchange Commission, nor have any such documents been filed with or reviewed by any federal or state securities commission or regulatory authority of any country. No authority has passed upon the accuracy or adequacy of the Consent Solicitation Statement or any related documents, and it is unlawful and may be a criminal offense to make any representation to the contrary.

The Consent Solicitation was made solely on the terms and conditions set forth in the Consent Solicitation Statement. Under no circumstances shall this press release constitute an offer to buy or the solicitation of an offer to sell the Notes or any other securities of the Company or any of its affiliates. The Consent Solicitation has not been made to, nor has the Company accepted deliveries of consents from, holders in any jurisdiction in which the Consent Solicitation or the acceptance thereof would not have been in compliance with the securities or blue sky laws of such jurisdiction. This press release is also not a solicitation of consents to effect the Proposed Amendment.

ABOUT GEOPARK

GeoPark is a leading independent energy company with over 20 years of successful operations across Latin America.

For further information, please contact:

INVESTORS:
Maria Catalina Escobar Shareholder Value and Capital Markets Director	mescobar@geo-park.com
Miguel Bello Investor Relations Officer	mbello@geo-park.com
Maria Alejandra Velez Investor Relations Leader	mvelez@geo-park.com
MEDIA:
Communications Department	communications@geo-park.com

CAUTIONARY STATEMENTS RELEVANT TO FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often are preceded by words such as “believes,” “expects,” “may,” “anticipates,” “plans,” “intends,” “assumes,” “will” or similar expressions. The forward-looking statements contained herein include statements about the consent solicitation, the acquisition of our common shares by Jaime Gilinski Bacal and Grupo Gilinski, and the proposed major strategic entry into Venezuela through the Bare field. These expectations may or may not be realized. Some of these expectations may be based upon assumptions or judgments that prove to be incorrect. In addition, GeoPark’s business and operations involve numerous risks and uncertainties, many of which are beyond the control of GeoPark, which could result in GeoPark’s expectations not being realized or otherwise materially affect the financial condition, results of operations and cash flows of GeoPark. Some of the factors that could cause future results to materially differ from recent results or those projected in forward-looking statements are described in GeoPark’s filings with the United States Securities and Exchange Commission.

The forward-looking statements are made only as of the date hereof, and GeoPark does not undertake any obligation to (and expressly disclaims any obligation to) update any forward-looking statements to reflect events or circumstances after the date such statements were made, or to reflect the occurrence of unanticipated events. In light of the risks and uncertainties described above, and the potential for variation of actual results from the assumptions on which certain of such forward-looking statements are based, investors should keep in mind that the results, events or developments disclosed in any forward-looking statement made in this document may not occur, and that actual results may vary materially from those described herein, including those described as anticipated, expected, targeted, projected or otherwise.

-Fiscal 2026 Revenue Increased 85% to $20.1 Million-

-Stock Locate Revenue Grew to $6.8 Million from $0.3 Million; Non-Commission Sources Reached 54% of Total Revenue-

-Second Consecutive Year of Positive GAAP Net Income of $2.0 Million, Including Non-Cash Fair-Value Gains-

-Cash More Than Doubled to $15.4 Million; Stockholders’ Equity Improved to $21.1 Million from a $(6.8) Million Deficit-

-AtlasClearing Net Capital Increased 29% to $14.4 Million-

-Five New Correspondent Broker-Dealers Signed; a Sixth signed after year-end-

-Fiscal 2026 Growth Achieved Without At-the-Market or Equity Line Financing-

-Earnings Conference Call Scheduled for Thursday, September 24, 2026, at 8:30 a.m. E.T.-

TAMPA, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a company building regulated financial infrastructure for smaller institutions, fintechs and advisors, today announced financial results for its fiscal year ended June 30, 2026. Results include those of the Company’s wholly owned correspondent clearing subsidiary, AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.) (“AtlasClearing”).

Fiscal Year 2026 Financial Highlights:
(Fiscal Year Ended June 30, 2026)

• Total revenue increased 85% to $20.1 million, compared to $10.9 million in fiscal 2025.
• Total revenue plus interest income, a non-GAAP measure, increased approximately 70% to $21.9 million, compared to approximately $12.9 million in fiscal 2025. A reconciliation to the most directly comparable GAAP measure is included below.
• Commission revenue increased 56% to $9.3 million, compared to $5.9 million. Stock locate revenue grew to $6.8 million from approximately $0.3 million and represented approximately 34% of total revenue.
• Sources other than commissions accounted for approximately 54% of total revenue, compared to approximately 45% in fiscal 2025.
• Loss from operations was $9.8 million, compared to $4.9 million in fiscal 2025, as higher activity drove increased variable compensation, data processing, clearing and stock locate costs. The year also included $3.6 million of non-cash stock-based compensation related to executive employment agreements entered into in September 2025.
• Net income was $2.0 million, or $0.02 per basic and diluted share, the Company’s second consecutive year of positive GAAP net income, compared to net income of $5.8 million, or $0.96 per share, in fiscal 2025. Fiscal 2026 net income includes substantial non-cash fair-value gains related to warrant, earnout and other derivative liabilities, most notably an $11.1 million gain on the earnout liability.
• Cash and cash equivalents totaled $15.4 million, more than double the $7.5 million reported at June 30, 2025.
• Stockholders’ equity improved to $21.1 million from a deficit of $(6.8) million at June 30, 2025. Total assets increased to $71.2 million from $60.9 million, and total liabilities declined approximately $17.6 million to approximately $50.1 million.
• AtlasClearing’s net capital increased 29% to $14.4 million, approximately $14.1 million above its minimum requirement and well above the $10 million excess net capital threshold that the National Securities Clearing Corporation (NSCC) requires of firms that clear for introducing brokers.
• The Company signed clearing agreements with six new correspondent broker-dealers. Fiscal 2026 results include no meaningful revenue from these relationships.
• The Company did not use an at-the-market program or equity line during fiscal 2026.
• Management concluded that substantial doubt about the Company’s ability to continue as a going concern had been alleviated, and that internal control over financial reporting was effective as of June 30, 2026 following remediation of the previously reported material weakness.

Management Commentary:

“Fiscal 2026 was a breakout year for AtlasClear,” said John Schaible, Executive Chairman of AtlasClear. “Revenue increased 85%, more than half of it now comes from sources other than commissions, and we achieved that growth without an at-the-market program or an equity line. We reported positive GAAP net income for the second consecutive year, and we want investors to have a clear view of both the reported results and the operating investments behind them: the GAAP result includes substantial non-cash fair-value gains, while at the operating level we invested in a business that is scaling quickly. We believe the platform we have been building is beginning to deliver meaningful scale.”

“Fiscal 2026 was a year of strong execution at AtlasClearing,” said Craig Ridenhour, President of AtlasClear. “Commissions grew 56%, stock locate went from approximately $0.3 million to $6.8 million, and net capital finished the year up 29%. We have signed six new correspondent broker-dealers, and none of their revenue is meaningfully reflected in these results. As they come online, the customer assets and trading activity they bring should help us scale our stock loan business and create additional sources of interest income, and we expect to support that growth with the platform and team already in place, with only incremental additional expense.”

Operational and Strategic Highlights:

• Correspondent clearing: AtlasClearing has signed clearing agreements with six new correspondent broker-dealers, the sixth of which was executed in September 2026, following fiscal year-end. These firms are in various stages of onboarding and conversion, and the Company expects them to begin contributing to results as they come online during fiscal 2027.
• Stock loan and interest income: The customer assets and trading activity brought by these correspondents are expected to help scale the Company’s stock loan business and create additional sources of interest income, including income from margin balances, customer cash and securities lending.
• Bank acquisition: The Company remains committed to its planned acquisition of Commercial Bancorp of Wyoming, the parent company of Farmers State Bank. As disclosed in the Company’s Annual Report on Form 10-K, the parties withdrew the pending regulatory applications and expect to refile them at an appropriate time. The transaction remains subject to regulatory approval and other customary closing conditions. The Company continues to view the combination of the bank and AtlasClearing as a cornerstone of its strategy to build an integrated trading, clearing, settlement and banking platform.
• Additional strategic opportunities: The Company is evaluating further strategic opportunities, including Ark Financial Services, Inc., the holding company of Dawson James Securities, Inc., and the previously announced acquisition of an institutional digital asset business. Both remain subject to non-binding letters of intent, due diligence, board approvals, definitive agreements and other closing conditions.

Fiscal Year 2026 Financial Results:

Revenue. Total revenue for fiscal 2026 was $20.1 million, an increase of 85% from $10.9 million in fiscal 2025. Commission revenue increased 56% to $9.3 million from $5.9 million, and stock locate fees increased to $6.8 million from $0.3 million. Clearing fees were $2.1 million, compared with $3.2 million, and vetting fees were $1.4 million, broadly consistent with $1.5 million a year ago. Net gains on firm trading accounts increased to $0.5 million from less than $0.1 million, and other revenue was $65,000.

Expenses and operating results. Total expenses were $29.8 million, compared with $15.8 million in fiscal 2025. Compensation, payroll taxes and benefits increased 91% to $11.7 million from $6.2 million, primarily because of higher variable compensation associated with revenue growth. Separately, the Company recorded $3.6 million of non-cash stock-based compensation related to executive employment agreements entered into in September 2025, with no comparable expense in fiscal 2025. Data processing and clearing costs increased 98% to $4.2 million from $2.1 million, generally in line with the higher level of activity. The Company also recorded $0.8 million of stock locate expense and $0.7 million of Loanet expense, both new cost categories associated with the growth of the stock locate business. Regulatory, professional and related expenses increased 17% to $4.9 million from $4.1 million, primarily reflecting professional fees related to the Commercial Bancorp negotiations and additional consulting support. Loss from operations was $9.8 million, compared with $4.9 million in fiscal 2025.

Other income and net income. Total other income was $11.5 million, compared with $10.4 million a year ago. The principal items included non-cash gains of $11.1 million from the change in fair value of the earnout liability, $1.8 million related to the Winston & Strawn agreement, $1.7 million from the change in fair value of warrant liabilities, and $0.4 million from the change in fair value of the convertible-note derivative, partially offset by $5.1 million of interest expense and a $570,000 loss on settlement of the Winston & Strawn agreement. Income before taxes was $1.7 million. After a tax benefit of $0.3 million, net income was $2.0 million, or $0.02 per basic and diluted share, based on weighted-average shares outstanding of approximately 125.0 million. This compares with net income of $5.8 million, or $0.96 per share, in fiscal 2025, which included a $12.4 million non-cash gain from changes in the fair value of long-term and short-term note derivatives.

Balance sheet, liquidity and cash flow. The Company ended fiscal 2026 with cash and cash equivalents of $15.4 million, compared with $7.5 million a year earlier. Total assets increased to $71.2 million from $60.9 million, stockholders’ equity improved to $21.1 million from a deficit of $(6.8) million, and total liabilities declined by approximately $17.6 million. Shares outstanding were approximately 150.3 million at fiscal year-end. Cash used in operating activities was $6.2 million, compared with cash provided by operating activities of $0.8 million in fiscal 2025, reflecting growth in operating assets as the business expanded and the non-cash nature of a substantial portion of fiscal 2026 net income. Cash used in investing activities was $65,000, representing a payment related to the extension of the Commercial Bancorp acquisition agreement. Cash provided by financing activities was $16.5 million, compared with $1.6 million in fiscal 2025, driven primarily by financing transactions completed during the year and partially offset by transaction costs, repayments and a $1.0 million cash payment related to the Winston & Strawn settlement. The Company sold no shares under its equity line facility during fiscal 2026 and has not conducted an at-the-market offering or other dilutive capital raise since its October 2025 institutional unit financing.

AtlasClearing’s $10 million revolving line of credit with BMO Harris Bank remained undrawn throughout the year, and the Company was in compliance with all applicable financial covenants as of June 30, 2026. Based on the capital raised and management’s operating cash-flow forecasts, management concluded that substantial doubt about the Company’s ability to continue as a going concern had been alleviated. Management also concluded that disclosure controls and internal control over financial reporting were effective as of June 30, 2026, following remediation of the previously reported material weakness.

Non-GAAP Financial Measure:
Total revenue plus interest income is a supplemental measure that is not calculated in accordance with U.S. generally accepted accounting principles (GAAP). It is the sum of total revenue and interest income, each as reported in the Company’s consolidated statement of operations, and is presented because interest earned on balances held by the Company’s broker-dealer subsidiary is an integral part of its operating economics. Interest income is presented in other income under GAAP. This measure should not be considered a substitute for total revenue determined in accordance with GAAP.

Reconciliation: Fiscal 2026 GAAP total revenue of $20.1 million plus interest income of $1.8 million equals total revenue plus interest income of $21.9 million. Fiscal 2025 GAAP total revenue of $10.9 million plus interest income of $2.0 million equals total revenue plus interest income of $12.9 million.

Earnings Conference Call Information:
Date: Thursday, September 24, 2026
Time: 8:30 a.m. Eastern Time
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1776661&tp_key=1331c6d174
Participant Dial-In: 1-877-407-0752 (toll-free) or 1-201-389-0912 (international)
Call me™ Link: https://callme.viavid.com/viavid/?callme=true&passcode=13756265&h=true&info=company&r=true&B=6
Telephone Replay: 1-844-512-2921 (toll-free) or 1-412-317-6671 (international)
Access ID: 13762839
Replay Available Through: Thursday, October 8, 2026, at 11:59 p.m. ET

About AtlasClear Holdings, Inc.
AtlasClear Holdings, Inc. (NYSE American: ATCH) is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear seeks to deliver a vertically integrated suite of brokerage, clearing, risk management, regulatory, and commercial banking solutions. For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

To stay up to date on AtlasClear’s platform strategy and market perspective, subscribe to the Company’s YouTube channel and watch the Clearing the View by AtlasClear video series

Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect AtlasClear Holdings’ current views with respect to, among other things, its future operations and financial performance. Forward-looking statements in this communication may be identified by the use of words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions.
Forward-looking statements include, but are not limited to, statements regarding expected future growth, strategic initiatives, the onboarding and conversion of the Company’s newly signed correspondent broker-dealers and the timing and revenue contribution of those relationships, the expansion of the Company’s stock locate, stock loan, securities lending and margin businesses, the Company’s future financing activities, the proposed acquisition of Commercial Bancorp of Wyoming, the proposed acquisition of an institutional digital asset business and the proposed acquisition of Ark Financial Services, Inc. and its subsidiary Dawson James Securities, Inc., the anticipated timing and completion of the initial and second closings of the Dawson James transaction, the execution of definitive documentation, receipt of FINRA, banking and other required regulatory and stockholder approvals, the anticipated growth of Dawson James’s clearing activity through AtlasClearing, the expected revenue, net income and EBITDA contributions of the proposed acquisitions, future financial performance, future capital markets activity, and the Company’s ability to execute on its business strategy. The letter of intent for the digital asset acquisition and the amended Dawson James letter of intent are non-binding (other than certain customary provisions), and there can be no assurance that definitive agreements will be executed or that the proposed acquisitions will be completed on the terms described, or at all.
These statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond the Company’s control, and actual results may differ materially from those anticipated. Factors that could cause actual results to differ include, but are not limited to: the Company’s failure to enter into definitive agreements with the digital asset business or the Dawson James parties, or its failure to complete the proposed acquisitions on favorable terms or at all; failure to receive the required regulatory approvals for the proposed acquisitions, including the acquisition of Commercial Bancorp of Wyoming; the Company’s inability to integrate, and to realize the benefits of, the proposed acquisitions; delays in onboarding correspondent broker-dealers or the failure of correspondent relationships to generate the anticipated revenue; changes in general economic or political conditions; changes in the markets that AtlasClear targets; slowdowns in securities or digital asset trading or shifting demand for trading, clearing and settling financial products; and any change in laws applicable to AtlasClear or any regulatory or judicial interpretation thereof. For additional information regarding risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2026. AtlasClear undertakes no obligation to update or revise forward-looking statements, except as required by law.

Company Contact:
AtlasClear Holdings, Inc.
Email: AtlasClearIR@atlasclear.com

Investor Relations Contact:
Jeff Ramson, CEO
PCG Advisory, Inc.
Email: jramson@pcgadvisory.com

Two industry leaders formalize strategic relationship spanning the full tungsten value chain

Investment includes a 4.99% ownership stake and multi-year supply agreements across key production stages

Further advances the objectives of the United States Government’s $450 million committed investment announced September 14, 2026

PORTLAND, Maine, Sept. 23, 2026 (GLOBE NEWSWIRE) — The Elmet Group Co. (NASDAQ: ELMT) (“ELMT” or the “Company”), a U.S.-based provider of critical materials, precision-engineered components, and advanced high-energy systems, today announced a long-term strategic relationship with Vietnam-based Masan High-Tech Materials Corporation (UPCoM: MSR) (“MSR”) under which ELMT will acquire a 4.99% equity stake in MSR for $124.75 million. The acquisition formalizes a longstanding commercial relationship of more than 12 years, during which MSR has distinguished itself as a reliable supplier of high-quality tungsten materials and a valued strategic partner to ELMT.

Alongside the equity investment, the parties have entered into long-term commercial agreements under which MSR has agreed to supply ELMT with mined tungsten from its Nui Phao Mine and provide tungsten conversion services from its refining complex in Vietnam. The acquisition of an ownership stake and the commercial agreements establish a basis for ELMT and MSR to pursue increased refining throughput, new product development, and a broader international customer base.

“We value the opportunity to formalize our relationship with MSR, which furthers our progress toward a resilient tungsten supply chain,” said The Elmet Group CEO and Chairman Peter V. Anania. “During the 12 years we have worked alongside MSR, it has established itself as a proven tungsten producer with global significance. The Elmet Group is investing in the expansion of supply, refinement, and conversion of tungsten through this acquisition, building on the landmark investment we received from the United States Government to solidify our position as a vertically integrated, U.S.-based provider of critical materials.”

The technologies defining this century, including artificial intelligence, semiconductors and aerospace, cannot exist without tungsten,” said Chairman of Masan-High Tech Materials Danny Le. “The world can count on one hand the places that produce and refine it at scale. MSR is one of them. The Elmet Group has spent twelve years inside our supply chain. They know what we have built and what it would take to build again. That is what trust looks like when it converts into capital. Their investment speaks for itself. This is the beginning, and we will unlock MSR’s full value for shareholders in Vietnam and beyond.”

Robust and Complementary Capabilities

Together, the two companies connect the supply chain from ore to finished part: mining and concentration, chemical conversion, powder production, pressing and sintering, forming, and precision machining. MSR sits upstream, operating the Nui Phao Mine — one of the largest tungsten deposits in the world — alongside an integrated refining complex that converts concentrate into high-purity tungsten chemicals. ELMT sits downstream, transforming the materials processed by MSR into precision-engineered components for aerospace, defense, semiconductor, medical, industrial, and energy customers. Few relationships in the tungsten industry span such a broad range, and even fewer are reinforced by an equity relationship.

For ELMT, this formalized relationship is intended to secure long-term access to mined tungsten and conversion capacity at scale. For MSR, it is intended to secure a committed downstream industrial partner, additional third-party feedstock for its refinery, and a strategic shareholder with deep manufacturing expertise and access to diverse end markets.

These announcements follow the landmark investment ELMT received from the United States Government, announced on September 14, 2026. Each of these developments advance ELMT’s aim to become a robust provider of critical materials with capabilities and access throughout the full tungsten supply chain across key geographies around the world.

Completion of the equity investment is subject to customary closing conditions, including required regulatory and corporate approvals, and is expected to occur in the third quarter of 2026. The commercial agreements take effect upon completion. In connection with its new ownership position, ELMT will also receive one seat on MSR’s Board of Directors and support MSR’s planned uplisting to the Ho Chi Minh Stock Exchange, as well as its evaluation of an international listing.

About Masan High-Tech Materials
Masan High-Tech Materials is a leading global provider of advanced tungsten materials used across critical industries, including electronics, chemicals, automotive, aerospace, energy, and pharmaceuticals, serving customers worldwide. As the world’s largest producer of midstream and downstream tungsten products outside China, the Company operates the Nui Phao polymetallic mine and a state-of-the-art tungsten processing facility in Thai Nguyen Province, Vietnam. Masan High-Tech Materials is also a leading global producer of fluorspar and bismuth.

About The Elmet Group
The Elmet Group is a U.S.-based provider of critical materials, precision-engineered components, and advanced high-energy systems for the Aerospace, Defense and Government, Industrial, Medical, Semiconductor and Electronics, and Energy industries. The Company operates through three divisions: Critical Materials Components (CMC), Engineered Microwave Products (EMP), and Elmet Refining & Trading (ERT), leveraging materials science and precision engineering expertise to deliver high-performance solutions. The Elmet Group is dedicated to strengthening domestic manufacturing capabilities to support the U.S. and its Allies’ needs in both critical materials and advanced high-power microwave systems.

Media Contact
media@theelmetgroup.com

Investor Contact
Tom Colton and Greg Bradbury
Gateway Group, Inc.
ELMT@gateway-grp.com
949-574-3860

Forward-looking statements disclaimer
The information in this press release includes forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. These statements generally relate to future events or our future financial or operating performance and include statements regarding (i) the purchase price and closing timing of ELMT’s acquisition of a 4.99% stake in MSR, (ii) the ability of ELMT and MSR to successfully pursue increased refining throughput, new product development, and a broader international customer base; (iii) the ability of ELMT to become a vertically integrated, U.S.-based provider of critical materials with capabilities and access throughout the full Tungsten supply chain across key geographies around the world; (iv) the receipt of regulatory and corporate approvals to complete the investment; (v) Elmet’s receipt of a board seat on MSR’s Board of Directors and MSR’s planned uplisting to the Ho Chi Minh Stock Exchange; and (vi) ELMT’s future performance, expected outcomes and strategic initiatives.

When used in this press release, words such as “expect,” “project,” “estimate,” “believe,” “anticipate,” “intend,” “plan,” “seek,” “forecast,” “target,” “predict,” “may,” “should,” “would,” “could,” and “will,” the negative of these terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Forward-looking statements are based on management’s current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Elmet’s Registration Statement on Form S-1, as amended (File No. 333-294725) and subsequent filings Elmet makes with the Securities and Exchange Commission. Elmet undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

MCDONALD, Tenn., Sept. 23, 2026 (GLOBE NEWSWIRE) — Amaero Inc. (ASX:3DA) (“Amaero” or the “Company”), a leading U.S.-based producer of high-value refractory and titanium alloy spherical metal powders for additive manufacturing and advanced manufacturing, and a pioneer in Powder Metallurgy Hot Isostatic Pressing manufacturing of large near-net-shape components, today announced the postponement of its initial public offering due to adverse market conditions.

A Registration Statement on Form S-1 (File No. 333-298612) relating to the proposed offering of securities was filed with the U.S. Securities and Exchange Commission (the “SEC”) but has not yet been declared effective. Such securities may not be sold nor may offers to buy such securities be accepted prior to the time the registration statement is declared effective.   

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

For further information, please contact:

Amaero Inc.
Hank J. Holland
Chairman and CEO
hank.holland@amaeroinc.com

Media & Investor Enquiries in Australia
Jane Morgan
Director
jm@janemorganmanagement.com.au

Media & Investor Enquiries in United States
Shannon Devine
MZ Group
amaero@mzgroup.us

About Amaero

Amaero Inc. is a leading U.S.-based producer of high-value refractory and titanium alloy spherical metal powders for additive manufacturing (“AM”) and advanced manufacturing, and a pioneer in Powder Metallurgy Hot Isostatic Pressing manufacturing of large near-net-shape components. With manufacturing and corporate headquarters in Tennessee, we occupy a strategically critical position at the intersection of U.S. national security priorities, AM technology, and the domestic reshoring of imperative U.S. supply chains.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain.

Notably, results from two positive Phase III studies evaluating the savolitinib and osimertinib combination have been selected for oral presentations. Results from the global SAFFRON study will be featured in the Presidential Symposium session, while results from the SANOVO study in China will be presented in a Proffered Paper session, both highlighting important new clinical data. Having two Phase III studies featured as late-breaking abstracts underscores the potential of this all-oral, chemo-free combination to deliver meaningful advancements for patients with non-small cell lung cancer (“NSCLC”).

The SAFFRON Global Phase III Study has been selected for a Presidential Symposium oral presentation. The study evaluated the combination in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC with MET overexpression or amplification following disease progression on osimertinib. The trial reported positive high-level results on August 17, 2026, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (“PFS”) and overall survival (“OS”) compared to doublet platinum-based chemotherapy.

The SANOVO China Phase III Study has been selected for a Proffered Paper oral presentation. The study evaluated the combination in previously untreated patients with locally advanced or metastatic NSCLC harboring activating EGFR mutations and MET overexpression. The trial reported positive high-level results on August 31, 2026, demonstrating a statistically significant and clinically meaningful improvement in PFS and a clinically meaningful benefit in OS versus osimertinib monotherapy.

Details of the presentations are as follows:

Abstract title	Presenter / Lead author	Presentation details
SPONSORED STUDIES
Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results	Shun Lu (Shanghai, China)	LBA6 Presidential Symposium II Alicante Auditorium – Hall 6 Sunday, October 25, 2026 16:30 – 18:15 CEST
Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase 3 SANOVO Study	Yi-Long Wu (Guangzhou, China)	LBA69 Proffered paper 2: NSCLC, metastatic Alicante Auditorium – Hall 6 Monday, October 26, 2026 08:30 – 10:00 CEST
Updated results from a fruquintinib Expanded Access Program for patients with previously treated metastatic colorectal cancer	Stefan Kasper (Essen, Germany)	848P Poster Session: Colon cancer
Association between dose adjustment and treatment outcomes in patients with advanced renal cell carcinoma receiving fruquintinib plus sintilimab: A post-hoc analysis of the FRUSICA-2 trial	Yuanyuan Qu (Shanghai, China)	3655eP E-poster Session: Renal cancer
Efficacy of fruquintinib plus sintilimab in special populations with advanced renal cell carcinoma: A subgroup analysis of FRUSICA-2 study	Kaiwei Yang (Beijing, China)	3667eP E-poster Session: Renal cancer
Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer	Shukui Qin (Nanjing, China)	3156P Poster Session: Pancreatic cancer
INVESTIGATOR-INITIATED STUDIES
Fruquintinib plus capecitabine maintenance after first-line anti-EGFR antibody plus chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer: A phase Ib/II study	Lin Yang/ Letian Zhang (Beijing, China)	877eP E-poster Session: Colon cancer
Real-world effectiveness and safety of fruquintinib in patients with metastatic colorectal cancer in Spain: The FrESP study	Ana Fernandez Montes (Ourense, Spain)	880eP E-poster Session: Colon cancer
CONCEPT (COmbinatioN of CEtuximab Plus fruquintinib Treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer	Kefeng Ding (Hangzhou, China)	890eP E-poster Session: Colon cancer
A real-world study of low-dose fruquintinib combined with trifluridine/tipiracil hydrochloride (TAS-102) in the third-line and beyond treatment of metastatic colorectal cancer	Yuehong Cui/ Li Liang (Shanghai, China)	903eP E-poster Session: Colon cancer
Real-world outcomes with fruquintinib in heavily pretreated metastatic colorectal cancer: Impact of patient and disease characteristics	Maria Maddalena Laterza (Pozzuoli, Italy)	964eP E-poster Session: Colon cancer
A phase II, open-label, randomized study of doublet chemotherapy (FOLFOX or FOLFIRI) plus fruquintinib compared with doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab in second line setting for a metastatic colorectal cancer: ULYSSE- FFCD2406 – PRODIGE115 (trials in progress)	Jean Marc Phelip (Saint-Étienne, France)	991eTiP E-poster Session: Colon cancer
Phase II study of fruquintinib plus utidelone in platinum-resistant recurrent ovarian cancer (FRUTD Trial)	Zheng Feng (Shanghai, China)	1283P Poster Session: Gynaecological cancers
Fruquintinib plus eribulin in patients with metastatic HR+, HER2–breast cancer after progression on endocrine therapy plus CDK4/6 inhibitor: Updated results from a phase II study	Yuan Yuan (Nanjing, China)	1896eP E-poster Session: HR+ breast cancer
Fruquintinib plus sintilimab and XELOX as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, open-label, multicenter phase II study	Hua Wang (Nanchang, China)	2980eP E-poster Session: Oesophagogastric cancer
Fruquintinib plus cadonilimab and S-1 in previously treated unresectable locally advanced or metastatic esophageal squamous cell carcinoma: preliminary efficacy and safety results from a phase Ib/II study	Huiyan Luo (Guangzhou, China)	2981eP E-poster Session: Oesophagogastric cancer
Nanoliposomal irinotecan (nal-IRI) combined with fruquintinib as second-line treatment for advanced gastric cancer: A single-arm, open-label, dose-escalation and expansion phase I/II trial	Jieer Ying/ Qi Xu (Hangzhou, China)	2986eP E-poster Session: Oesophagogastric cancer
FRUQUITAS trial: ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma	David Tougeron (Poitiers, France)	3079eTiP E-poster Session: Oesophagogastric cancer
CHOICE III: short-course preoperative radiotherapy followed by fruquintinib plus anti–PD-1 antibody (serplulimab) for neoadjuvant treatment of pMMR/MSS mid-to-low locally advanced rectal cancer: A single-arm, single-center, prospective phase II study	Wei Zhang (Shanghai, China)	3582eTiP E-poster Session: Rectal and anal cancer
First-line fruquintinib plus serplulimab for metastatic non-clear cell renal cell carcinoma: Updated results from the phase II FRONTIER study	Jiwei Huang (Shanghai, China)	3614P Poster Session: Renal cancer
Latest efficacy and safety analysis of surufatinib combined with EP regimen and serplulimab as first-line treatment for extrapulmonary neuroendocrine carcinoma	Tao Zhang/ Zhenyu Lin (Wuhan, China)	2394RO Rapid Oral Session: NETs and endocrine tumours Pamplona Auditorium – Hall 5 Friday, October 23, 2026 16:15 – 17:45 CEST
Surufatinib combined with toripalimab and nab-paclitaxel/ gemcitabine chemotherapy as first-line treatment for advanced pancreatobiliary-type ampullary carcinoma: A prospective phase II Clinical Trial	Juan Du (Nanjing, China)	507eP E-poster Session: Biliary tract cancer, incl. cholangiocarcinoma
Efficacy and safety of surufatinib in combination with CAPTEM in advanced G2/G3 Neuroendocrine Tumors: Results from a single-arm, phase II Trial	Wei Wang (Guangzhou, China)	2403P Poster Session: Neuroendocrine tumours
Surufatinib plus S-1/temozolomide as first-line therapy in MGMT-low advanced pancreatic neuroendocrine tumours (SUSTEM-p): An open-label, single-centre phase Ib/II trial	Yihebali Chi (Beijing, China)	2411P Poster Session: Neuroendocrine tumours
Updated results of a prospective, open-label study of surufatinib plus CAPTEM as conversion therapy for unresectable pancreatic neuroendocrine tumors	Ziyao Wang (Chengdu, China)	2412P  Poster Session: Neuroendocrine tumours
Matching-adjusted indirect comparison of surufatinib versus high-dose OCT-LAR in patients with advanced GEP-NETs who progressed on prior SSA Therapy	Jianming Xu (Beijing, China)	2415P Poster Session: Neuroendocrine tumours
Surufatinib combined with octreotide LAR for the treatment of G1/G2 GEP-NETs: A single-arm, prospective, open-label phase II study	Xiaofeng Sun (Nanjing, China)	2439eP E-poster Session: Neuroendocrine tumours
Six weeks of induction gemcitabine plus nab paclitaxel (AG) followed by sequential surufatinib plus AG or AG alone as first line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): A single center, two cohort, phase II study	Jin Xu/ Jialin Li (Shanghai, China)	3168P Poster Session: Pancreatic cancer
A phase Ib/II study of radiotherapy combined with surufatinib and sintilimab for localized high-risk limb and trunk soft tissue sarcomas: A prospective single-center trial	Yan Wang (Shanghai, China)	3739P Poster Session: Sarcoma
Surufatinib plus serplulimab, etoposide, and carboplatin as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC): Updated results from a single-arm, phase Ia/Ib trial	Haipeng Xu/ Longfeng Zhang (Fuzhou, China)	3831P Poster Session: Small cell lung cancer

About Fruquintinib
Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE^®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA^®.

About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS^®.

About Surufatinib
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA^®. HUTCHMED currently retains all rights to surufatinib worldwide.

About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, surufatinib and savolitinib, the further clinical development for fruquintinib, surufatinib and savolitinib, its expectations as to whether any studies on fruquintinib, surufatinib and savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, surufatinib and savolitinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, surufatinib and savolitinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab and toripalimab as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000